New Filgrastim Biosimilar Approved by FDA

News
Article

Fourth filgrastim biosimilar from Sandoz, expected ASAP.

bacteria

The FDA has approved pegfilgrastim-bmez (Ziextenzo, Sandoz) to decrease the incidence of infection from febrile neutropenia in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a high incidence of febrile neutropenia. 

Pegfilgrastim-bmez is a long-acting biosimilar to filgrastim, a leukocyte growth factor similar to the granulocyte colony-stimulating factor protein. The recent approval marks the fourth filgrastim biosimilar approved under the Sandoz label. 

“When a cancer patient with febrile neutropenia gets an infection, it can have serious consequences such as delays or dose reductions of chemotherapy,” said Carol Lynch, president of Sandoz Inc, in a statement. “The approval of Ziextenzo expands our oncology portfolio, providing physicians with a long-acting supportive oncology biosimilar option. It builds on the foundation of trust and experience we developed with our short-acting filgrastim Zarxio-the leading filgrastim by market share in the US-including consistent product supply and reliable patient services.”

Trending: Study: Walking Speed Might Affect Cancer Outcomes

The approval is based upon results from a three-way pharmacokinetics and pharmacodynamics study, according to the news release. After comparing Sandoz pegfilgrastim with US-sourced reference pegfilgrastim, Sandoz pegfilgrastim with EU-sourced reference pegfilgrastim, and US-sourced with EU-Sourced reference pegfilgrastim, researchers found enough similarity between the pharmacokinetics and pharmacodynamics results to warrant safety and efficacy. 

Pegfilgrastim-bmez is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (i.e., Pegfilgrastim or Filgrastim products). 

Warnings and precautions issued with the use of pegfilgrastim-bmez include fatal splenic rupture; acute respiratory distress syndrome; and serious allergic reactions including anaphylaxis, fatal sickle cell crises, and glomerulonephritis.

Adverse reactions reported with the use of pegfilgrastim-bmez include pain in the bones and extremities. 

 

Full Prescribing Information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.